AstraZeneca Weight-Loss Pill Shows 12% Loss in Trials

Getting healthier just got a little easier. AstraZeneca's new weight-loss pill showed promising results in clinical trials, helping people lose up to 11.8% of their body weight without injections.

The pill, called elecoglipron, works similarly to popular GLP-1 drugs like Wegovy and Mounjaro but comes in tablet form instead of weekly shots. In a trial with 310 participants, people taking the highest dose lost an average of 10.5% of their weight at 26 weeks and 11.8% at 36 weeks.

That's real progress for anyone who has struggled with weight management. The medication suppresses appetite naturally, making it easier for people to adopt healthier eating habits without constant hunger pangs.

Side effects were mild and similar to other GLP-1 pills, with nausea being the most common complaint. The trial included overweight and obese adults without diabetes, showing the drug works for a broad range of people seeking weight management support.

Marie Spreckley, a weight management researcher at the University of Cambridge, noted the results look comparable to other oral GLP-1 medications already on the market. She wasn't involved in the study but reviewed the findings published in The Lancet medical journal.

Why This Inspires

This breakthrough matters because options empower people. Some patients prefer pills over injections, and having choices means doctors can match treatments to individual needs and preferences.

The growing competition in this space is driving innovation at record speed. Novo Nordisk and Eli Lilly already offer pill versions of their blockbuster drugs, with Eli Lilly's Foundayo approved in the United States in April and Novo Nordisk's oral Wegovy getting the green light in Europe last month.

More companies entering the market typically means better access and lower costs over time. As these medications become more available, millions more people could get the support they need to reach healthier weights.

The next phase of testing will involve larger groups over longer periods to confirm these results hold up. Researchers will also establish the drug's long-term safety profile and figure out exactly where it fits among the expanding range of obesity treatments.

For now, the results offer genuine hope that managing weight could become simpler and more accessible for millions of people worldwide.